Type-2 Diabetes treated with insulin
Conditions
Interventions
Trade Name: Insulin Actrapid Penfill 100 I.E./ml-Inj.-Lösung
Product Name: Insulin Actrapid Penfill 100 I.E./ml-Inj.-Lösung in einer Zylinderampulle
Pharmaceutical Form: Solution for injection
Trade
Sponsors
Dept. of Internal Medicine
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: Typ 2 Diabetes BMI > 27 kg/m2 Treatment with insulin alone or in combination with metformin Are the trial subjects under 18? no Number of subjects for this age range: F.1.2 Adults (18-64 years) yes F.1.2.1 Number of subjects for this age range F.1.3 Elderly (>=65 years) yes F.1.3.1 Number of subjects for this age range
Exclusion criteria
Exclusion criteria: HbA1c > 9.5 % Serum Kreatinin > 1.7 mg/dl ALT or AST > 3x ULN
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Main Objective: Investigate whether NovoRapid or Actrapid exert different effects on postprandial lipid and glucose metabolism during 2 consecutive meals.;Secondary Objective: N.A.;Primary end point(s): glucose area over basal for each single meal and combined triglyceride area over basal for each single meal and combined | — |
Countries
Austria
Outcome results
None listed